Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has successfully upsized its offering of senior notes to approximately $2.3 billion, increasing from a previously announced $2 billion, with proceeds intended for tender offers and debt repayment [1][3]. Group 1: Offering Details - The offering consists of €1 billion of 4.125% EUR-denominated Senior Notes maturing in 2031, $500 million of 6.000% USD-denominated Senior Notes maturing in 2032, and $700 million of 5.750% USD-denominated Senior Notes maturing in 2030 [2]. - The settlement of the notes is expected to occur on or about May 28, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund tender offers for various senior notes, pay associated fees and expenses, and repay outstanding debt upon maturity or earlier redemption [1]. Group 3: Company Background - Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader with over 120 years of commitment to health, employing 37,000 people across 57 markets to develop medicines and produce generics and biologics [6][7].